A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2002-2009

ABSTRACT

This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic material) of four HIV proteins called 'gag', 'pol', 'Nef', and 'Env'. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. This study will see if the body then creates an immune response to these proteins. Study participants cannot catch HIV or AIDS from the DNA vaccine or any proteins made from it. Healthy normal volunteers between 18 and 40 years of age may be eligible for this study. Candidates will be screened with a medical history, physical examination and blood and urine tests. Women will also have a pregnancy test. Women enrolled in the study must either be infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from heterosexual sex or to practice birth control for at least 21 days before beginning the study and throughout its duration. Participants will be randomly assigned to receive either the experimental vaccine or a placebo (a salt solution that does not contain any active substance) and will be divided into three groups, based on their entry into the study. Of the first seven people enrolled (Group 1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an 8-mg dose of vaccine and six will receive placebo. All participants will receive three injections in an upper arm muscle-one injection a month for three months-with a needle-less device called a Biojector 2000® (Registered Trademark). At the time of each injection, participants will be observed for at least 1 hour after immunization. At home, they will record their temperature and any symptoms they may experience, including any effects at the injection site, for at least 7 days, or as long as the symptoms remain. If symptoms occur, participants will report them immediately to the clinic staff and, if necessary, come to the clinic for an examination. Participants will have about 10 clinic visits during the study. Most visits will last about 2 hours; those on vaccination days will last about 4 hours. ... Detailed Description This is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VRC-HIVDNA009-00-VP and secondary objectives are to evaluate the immunogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial. More... »

URL

https://clinicaltrials.gov/show/NCT00047931

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic material) of four HIV proteins called 'gag', 'pol', 'Nef', and 'Env'. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. This study will see if the body then creates an immune response to these proteins. Study participants cannot catch HIV or AIDS from the DNA vaccine or any proteins made from it. Healthy normal volunteers between 18 and 40 years of age may be eligible for this study. Candidates will be screened with a medical history, physical examination and blood and urine tests. Women will also have a pregnancy test. Women enrolled in the study must either be infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from heterosexual sex or to practice birth control for at least 21 days before beginning the study and throughout its duration. Participants will be randomly assigned to receive either the experimental vaccine or a placebo (a salt solution that does not contain any active substance) and will be divided into three groups, based on their entry into the study. Of the first seven people enrolled (Group 1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an 8-mg dose of vaccine and six will receive placebo. All participants will receive three injections in an upper arm muscle-one injection a month for three months-with a needle-less device called a Biojector 2000\u00ae (Registered Trademark). At the time of each injection, participants will be observed for at least 1 hour after immunization. At home, they will record their temperature and any symptoms they may experience, including any effects at the injection site, for at least 7 days, or as long as the symptoms remain. If symptoms occur, participants will report them immediately to the clinic staff and, if necessary, come to the clinic for an examination. Participants will have about 10 clinic visits during the study. Most visits will last about 2 hours; those on vaccination days will last about 4 hours. ...\n\nDetailed Description\nThis is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VRC-HIVDNA009-00-VP and secondary objectives are to evaluate the immunogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial.", 
    "endDate": "2009-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00047931", 
    "keywords": [
      "Phase I clinical trial", 
      "Evaluate", 
      "safety", 
      "DNA plasmid", 
      "VRC", 
      "adult volunteer", 
      "experimental vaccine", 
      "HIV", 
      "immune response", 
      "vaccine", 
      "substance", 
      "resistance", 
      "immunity", 
      "disease", 
      "infection", 
      "DNA", 
      "gene", 
      "HIV protein", 
      "pol", 
      "Nef", 
      "Env", 
      "viral DNA", 
      "body", 
      "small amount", 
      "protein", 
      "study participant", 
      "HIV or AIDS", 
      "DNA vaccine", 
      "volunteer", 
      "age", 
      "medical history", 
      "physical examination", 
      "blood", 
      "urine test", 
      "woman", 
      "pregnancy", 
      "infertile", 
      "menopause", 
      "hysterectomy", 
      "abstain", 
      "sex", 
      "practice", 
      "duration", 
      "placebo", 
      "salt solution", 
      "active substance", 
      "entry", 
      "Group 1", 
      "dose", 
      "Group 2", 
      "Group 3", 
      "injection", 
      "upper arm", 
      "needle", 
      "immunization", 
      "home", 
      "temperature", 
      "symptom", 
      "injection site", 
      "clinic staff", 
      "clinic", 
      "examination", 
      "Ambulatory Care", 
      "visit", 
      "dose escalation study", 
      "tolerability", 
      "HIV DNA", 
      "plasmid", 
      "human administration", 
      "primary objective", 
      "human", 
      "secondary objective", 
      "immunogenicity", 
      "Social Change", 
      "vaccine trial"
    ], 
    "name": "A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00047931"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00000.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419681.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2002-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1086/509259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015613412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-80475-5_8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039018313", 
          "https://doi.org/10.1007/978-3-642-80475-5_8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0598supp-532", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040892052", 
          "https://doi.org/10.1038/nm0598supp-532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.med.53.082901.104035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052197384"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00047931"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00047931'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00047931'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00047931'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00047931'


 

This table displays all metadata directly associated to this object as RDF triples.

113 TRIPLES      16 PREDICATES      96 URIs      84 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00047931 schema:about anzsrc-for:3053
2 anzsrc-for:3103
3 schema:description This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic material) of four HIV proteins called 'gag', 'pol', 'Nef', and 'Env'. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. This study will see if the body then creates an immune response to these proteins. Study participants cannot catch HIV or AIDS from the DNA vaccine or any proteins made from it. Healthy normal volunteers between 18 and 40 years of age may be eligible for this study. Candidates will be screened with a medical history, physical examination and blood and urine tests. Women will also have a pregnancy test. Women enrolled in the study must either be infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from heterosexual sex or to practice birth control for at least 21 days before beginning the study and throughout its duration. Participants will be randomly assigned to receive either the experimental vaccine or a placebo (a salt solution that does not contain any active substance) and will be divided into three groups, based on their entry into the study. Of the first seven people enrolled (Group 1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an 8-mg dose of vaccine and six will receive placebo. All participants will receive three injections in an upper arm muscle-one injection a month for three months-with a needle-less device called a Biojector 2000® (Registered Trademark). At the time of each injection, participants will be observed for at least 1 hour after immunization. At home, they will record their temperature and any symptoms they may experience, including any effects at the injection site, for at least 7 days, or as long as the symptoms remain. If symptoms occur, participants will report them immediately to the clinic staff and, if necessary, come to the clinic for an examination. Participants will have about 10 clinic visits during the study. Most visits will last about 2 hours; those on vaccination days will last about 4 hours. ... Detailed Description This is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VRC-HIVDNA009-00-VP and secondary objectives are to evaluate the immunogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial.
4 schema:endDate 2009-05-01T00:00:00Z
5 schema:keywords Ambulatory Care
6 DNA
7 DNA plasmid
8 DNA vaccine
9 Env
10 Evaluate
11 Group 1
12 Group 2
13 Group 3
14 HIV
15 HIV DNA
16 HIV or AIDS
17 HIV protein
18 Nef
19 Phase I clinical trial
20 Social Change
21 VRC
22 abstain
23 active substance
24 adult volunteer
25 age
26 blood
27 body
28 clinic
29 clinic staff
30 disease
31 dose
32 dose escalation study
33 duration
34 entry
35 examination
36 experimental vaccine
37 gene
38 home
39 human
40 human administration
41 hysterectomy
42 immune response
43 immunity
44 immunization
45 immunogenicity
46 infection
47 infertile
48 injection
49 injection site
50 medical history
51 menopause
52 needle
53 physical examination
54 placebo
55 plasmid
56 pol
57 practice
58 pregnancy
59 primary objective
60 protein
61 resistance
62 safety
63 salt solution
64 secondary objective
65 sex
66 small amount
67 study participant
68 substance
69 symptom
70 temperature
71 tolerability
72 upper arm
73 urine test
74 vaccine
75 vaccine trial
76 viral DNA
77 visit
78 volunteer
79 woman
80 schema:name A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers
81 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00047931
82 schema:sdDatePublished 2019-03-07T15:21
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N6c848b384fee4bccbaaa6355e63c356a
85 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
86 https://www.grid.ac/institutes/grid.419681.3
87 schema:startDate 2002-10-01T00:00:00Z
88 schema:subjectOf sg:pub.10.1007/978-3-642-80475-5_8
89 sg:pub.10.1038/nm0598supp-532
90 https://doi.org/10.1086/509259
91 https://doi.org/10.1146/annurev.med.53.082901.104035
92 schema:url https://clinicaltrials.gov/show/NCT00047931
93 sgo:license sg:explorer/license/
94 sgo:sdDataset clinical_trials
95 rdf:type schema:MedicalStudy
96 N6c848b384fee4bccbaaa6355e63c356a schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
99 rdf:type schema:DefinedTerm
100 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
101 rdf:type schema:DefinedTerm
102 sg:pub.10.1007/978-3-642-80475-5_8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039018313
103 https://doi.org/10.1007/978-3-642-80475-5_8
104 rdf:type schema:CreativeWork
105 sg:pub.10.1038/nm0598supp-532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040892052
106 https://doi.org/10.1038/nm0598supp-532
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1086/509259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015613412
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1146/annurev.med.53.082901.104035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052197384
111 rdf:type schema:CreativeWork
112 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
113 https://www.grid.ac/institutes/grid.419681.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...